Elanco Animal Health Shares Resume Trade
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/19/2024 | $17.00 → $15.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2024 | $13.00 → $20.00 | Hold → Buy | Stifel |
| 12/19/2023 | $17.00 | Buy | Jefferies |
| 12/15/2023 | $16.00 | Equal-Weight → Overweight | Morgan Stanley |
| 12/7/2023 | $18.00 | Outperform | Exane BNP Paribas |
| 4/20/2023 | $14.00 | Equal Weight → Overweight | Barclays |
| 8/18/2022 | $37.00 → $22.00 | Overweight → Equal-Weight | Morgan Stanley |
| 8/16/2022 | $28.00 → $24.00 | Overweight → Neutral | JP Morgan |
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
3 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
4 - Elanco Animal Health Inc (0001739104) (Issuer)
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
New Directors Join the Board's Renamed Finance, Strategy and Oversight Committee Reaches Cooperation Agreement with Ancora GREENFIELD, Ind., April 1, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced that it has appointed two new independent directors, Kathy Turner and Craig Wallace, to its Board of Directors (the "Board"), effective immediately, expanding the Board to 14 members. Ms. Turner brings significant global experience in both the animal health and broader healthcare industries. She has held senior leadership positions at IDEXX Labora
GREENFIELD, Ind., March 4, 2024 /PRNewswire/ -- Elanco Animal Health (NYSE:ELAN) announced today the appointment of Shiv O'Neill as the company's Executive Vice President, General Counsel and Corporate Secretary. O'Neill will be responsible for the global strategy and operations of the Company's legal team, ethics & compliance organization and ESG efforts. "Shiv's ability to deliver strategic value to Elanco in the short term serving as our interim general counsel combined with her robust experience made it clear that she was the right person for this role," said Jeff Simmons,
8-K - Elanco Animal Health Inc (0001739104) (Filer)
10-Q - Elanco Animal Health Inc (0001739104) (Filer)
8-K - Elanco Animal Health Inc (0001739104) (Filer)
Merck & Company (NYSE:MRK) completed the acquisition of the aquaculture business part of Elanco Animal Health (NYSE:ELAN). What Happened: Elanco completed the sale for about $1.3 billion in cash. Upon completion, Elanco expects to have between $1.05 billion and $1.1 billion available for debt paydown. “With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition,” said Rick DeLuca, president of Merck Animal Health. In addition, Merk Animal Health now owns products including CLYNAV, a DNA-based vaccine that pr
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners named Citigroup Inc. (NYSE:C), which is scheduled to release earnings on Friday. “The market believes it’s going to be good, so do I,” he said. Analysts expect Citigroup to report quarterly earnings at $1.41 per share, up from $1.33 per share in the year-ago period. The bank is projected to report revenue of $20.08 billion, compared to $19.44 billion in the year-earlier quarter. Stephanie Link of Hightower picked Elanco Animal Health Incorporated (NYSE:ELAN). “I like it on the buy because they have a lot of new products coming,” she added. On June 27, Elanco Animal Health released updates to the expected FDA
- CNBC
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
SC 13G/A - Elanco Animal Health Inc (0001739104) (Subject)
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily
Ma brings deep manufacturing and innovation expertise GREENFIELD, Ind., Nov. 12, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today announced the appointment of Dr. Stacey Ma to its Board of Directors, effective immediately. Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, further strengthening Elanco's expertise in these critical areas. "We are delighted to add Stacey to the Elanco Board," said Lawrence Kurzius, Chairman of the Elanco Board of Directors. "Her deep understanding of product developmen
GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de
Morgan Stanley downgraded Elanco Animal Health from Overweight to Equal-Weight and set a new price target of $15.00 from $17.00 previously
Stifel upgraded Elanco Animal Health from Hold to Buy and set a new price target of $20.00 from $13.00 previously
Jefferies initiated coverage of Elanco Animal Health with a rating of Buy and set a new price target of $17.00
GREENFIELD, Ind., Nov. 15, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) today acquired a contract manufacturing facility and related assets in Speke, UK. The facility, previously owned by TriRx Speke Ltd., was under trading administration, a formal insolvency process in the United Kingdom. As previously shared on the Company's third quarter 2024 earnings call, the Speke facility plays a vital role for Elanco in producing a number of farm animal product lines, representing approximately $160 million to $180 million in annual farm animal revenue, primarily
GREENFIELD, Ind., Oct. 10, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its third quarter 2024 financial results on Thursday, November 7, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance. The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/de
U.S. Food and Drug Administration approves Zenrelia, a once-daily oral JAK inhibitor for dogs with allergic and atopic dermatitisElanco enters the estimated $1.7 billion global canine dermatology market, highly accretive to existing portfolioIn a head-to-head study, Zenrelia was shown to be at least as effective as the market incumbent JAK inhibitor at the primary end point, with an additional endpoint at which Zenrelia got 77% of dogs to clinical remission of itch, compared to 53% of dogs treated with Apoquel® (oclacitinib tablet)1*Zenrelia launch begins in U.S. with Elanco now taking orders; product expected to ship in coming daysGREENFIELD, Ind., Sept. 19, 2024 /PRNewswire/ -- Elanco Anim